Clinical Research Directory
Browse clinical research sites, groups, and studies.
sCD163 in PBC Patients - Assessment of Treatment Response
Sponsor: University of Aarhus
Summary
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.
Official title: Macrophage Activation Marker sCD163 in PBC Patients - Assessment of Treatment Response to UDCA
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
40
Start Date
2016-09
Completion Date
2031-09
Last Updated
2022-08-12
Healthy Volunteers
No
Interventions
Blood samples
Fibroscan
Questionnaires
Liver biopsy
Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
Locations (1)
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
Aarhus C, Central Jutland, Denmark